|
Market Analysis Reports of C5a Anaphylatoxin (37-53) (Human)
|
Complement C5 inhibitors - Pipeline Insight, 2022 ... prevents the generation of C5a, the most potent of the anaphylatoxins, and of the ... Pharmaceuticals Pozelimab is an investigational, fully-human monoclonal antibody designed to block complement ... to wild-type and variant human C5 and blocks its activity. ...
|
|
|